About: African Academy of Sciences is a facility organization based out in Nairobi, Kenya. It is known for research contribution in the topics: Hot working & Strain rate. The organization has 48 authors who have published 68 publications receiving 883 citations. The organization is also known as: AAS.
Papers published on a yearly basis
Imperial College London1, University of London2, National Institute for Medical Research3, University of Copenhagen4, Kwame Nkrumah University of Science and Technology5, NewYork–Presbyterian Hospital6, Kenya Medical Research Institute7, University of North Carolina at Chapel Hill8, Centers for Disease Control and Prevention9, Ifakara Health Institute10, Eduardo Mondlane University11, University of Barcelona12, Wellcome Trust13, African Academy of Sciences14, University of Oxford15
TL;DR: Anti-circumsporozoite antibody titres are a surrogate of protection for the magnitude and duration of R TS,S/AS01 efficacy, with or without a booster dose, providing a valuable surrogate of effectiveness for new RTS,S formulations in the age groups considered.
Abstract: Summary Background The RTS,S/AS01 malaria vaccine targets the circumsporozoite protein, inducing antibodies associated with the prevention of Plasmodium falciparum infection. We assessed the association between anti-circumsporozoite antibody titres and the magnitude and duration of vaccine efficacy using data from a phase 3 trial done between 2009 and 2014. Methods Using data from 8922 African children aged 5–17 months and 6537 African infants aged 6–12 weeks at first vaccination, we analysed the determinants of immunogenicity after RTS,S/AS01 vaccination with or without a booster dose. We assessed the association between the incidence of clinical malaria and anti-circumsporozoite antibody titres using a model of anti-circumsporozoite antibody dynamics and the natural acquisition of protective immunity over time. Findings RTS,S/AS01-induced anti-circumsporozoite antibody titres were greater in children aged 5–17 months than in those aged 6–12 weeks. Pre-vaccination anti-circumsporozoite titres were associated with lower immunogenicity in children aged 6–12 weeks and higher immunogenicity in those aged 5–17 months. The immunogenicity of the booster dose was strongly associated with immunogenicity after primary vaccination. Anti-circumsporozoite titres wane according to a biphasic exponential distribution. In participants aged 5–17 months, the half-life of the short-lived component of the antibody response was 45 days (95% credible interval 42–48) and that of the long-lived component was 591 days (557–632). After primary vaccination 12% (11–13) of the response was estimated to be long-lived, rising to 30% (28–32%) after a booster dose. An anti-circumsporozoite antibody titre of 121 EU/mL (98–153) was estimated to prevent 50% of infections. Waning anti-circumsporozoite antibody titres predict the duration of efficacy against clinical malaria across different age categories and transmission intensities, and efficacy wanes more rapidly at higher transmission intensity. Interpretation Anti-circumsporozoite antibody titres are a surrogate of protection for the magnitude and duration of RTS,S/AS01 efficacy, with or without a booster dose, providing a valuable surrogate of effectiveness for new RTS,S formulations in the age groups considered. Funding UK Medical Research Council.
••24 Feb 2021
TL;DR: A new release of curated genome variation data on 7,000 Plasmodium falciparum samples from MalariaGEN partner studies in 28 malaria-endemic countries aims to facilitate research into the evolutionary processes affecting malaria control and to accelerate development of the surveillance toolkit required for malaria elimination.
Abstract: MalariaGEN is a data-sharing network that enables groups around the world to work together on the genomic epidemiology of malaria. Here we describe a new release of curated genome variation data on 7,000 Plasmodium falciparum samples from MalariaGEN partner studies in 28 malaria-endemic countries. High-quality genotype calls on 3 million single nucleotide polymorphisms (SNPs) and short indels were produced using a standardised analysis pipeline. Copy number variants associated with drug resistance and structural variants that cause failure of rapid diagnostic tests were also analysed. Almost all samples showed genetic evidence of resistance to at least one antimalarial drug, and some samples from Southeast Asia carried markers of resistance to six commonly-used drugs. Genes expressed during the mosquito stage of the parasite life-cycle are prominent among loci that show strong geographic differentiation. By continuing to enlarge this open data resource we aim to facilitate research into the evolutionary processes affecting malaria control and to accelerate development of the surveillance toolkit required for malaria elimination.
Swiss Tropical and Public Health Institute1, University of Basel2, University of London3, University of Oxford4, Charles Darwin University5, Mahidol University6, Burnet Institute7, Monash University8, Liverpool School of Tropical Medicine9, African Academy of Sciences10, Kenya Medical Research Institute11
TL;DR: Experts working in malaria research and control are asked to discuss the ways in which malaria might eventually be eradicated, and their collective views highlight the challenges and opportunities.
Abstract: Although global efforts in the past decade have halved the number of deaths due to malaria, there are still an estimated 219 million cases of malaria a year, causing more than half a million deaths. In this forum article, we asked experts working in malaria research and control to discuss the ways in which malaria might eventually be eradicated. Their collective views highlight the challenges and opportunities, and explain how multi-factorial and integrated processes could eventually make malaria eradication a reality.
Leiden University Medical Center1, Swiss Tropical and Public Health Institute2, University of Basel3, University College London4, African Leaders Malaria Alliance5, African Academy of Sciences6, University of Texas at Austin7, Centers for Disease Control and Prevention8, National Institute for Medical Research9, University of Georgia10
TL;DR: The evolution of the CAA assay format during the SCORE period with emphasis on urine-based applications is reviewed, which demonstrated that frozen, banked urine specimens yielded similar results to fresh ones; pooling of specimens may be a useful, cost-effective approach for surveillance in some settings.
Abstract: The Schistosomiasis Consortium for Operational Research and Evaluation (SCORE) was funded in 2008 to conduct research that would support country schistosomiasis control programs. As schistosomiasis prevalence decreases in many places and elimination is increasingly within reach, a sensitive and specific test to detect infection with Schistosoma mansoni and Schistosoma haematobium has become a pressing need. After obtaining broad input, SCORE supported Leiden University Medical Center (LUMC) to modify the serum-based antigen assay for use with urine, simplify the assay, and improve its sensitivity. The urine assay eventually contributed to several of the larger SCORE studies. For example, in Zanzibar, we demonstrated that urine filtration, the standard parasite egg detection diagnostic test for S. haematobium, greatly underestimated prevalence in low-prevalence settings. In Burundi and Rwanda, the circulating anodic antigen (CAA) assay provided critical information about the limitations of the stool-based Kato-Katz parasite egg-detection assay for S. mansoni in low-prevalence settings. Other SCORE-supported CAA work demonstrated that frozen, banked urine specimens yielded similar results to fresh ones; pooling of specimens may be a useful, cost-effective approach for surveillance in some settings; and the assay can be performed in local laboratories equipped with adequate centrifuge capacity. These improvements in the assay continue to be of use to researchers around the world. However, additional work will be needed if widespread dissemination of the CAA assay is to occur, for example, by building capacity in places besides LUMC and commercialization of the assay. Here, we review the evolution of the CAA assay format during the SCORE period with emphasis on urine-based applications.
Showing all 49 results
|Berhanu M. Abegaz
|J. Catherine Ngila
|Dziedzom K. de Souza
|Thomas M. Kariuki
|Adeniyi Francis Fagbamigbe
|Mai F. Tolba
|Michael Oluwatosin Bodunrin
|Aderemi O. Kuku
Related Institutions (5)
Bill & Melinda Gates Foundation
2K papers, 80.7K citations
Institute of Tropical Medicine Antwerp
5.6K papers, 198.1K citations
University of Malawi
4.3K papers, 113.8K citations
World Health Organization
22.2K papers, 1.3M citations
Swiss Tropical and Public Health Institute
5.2K papers, 200.3K citations